Abiopharma

Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer: Change in Interest - Tan Ong Huat

Share Buy Back - Daily Share Buy-Back Notice: Share Buy Back - Daily Share Buy-Back Notice

Global-e Achieves Significant GMV, Revenue and Profit Expansion in the Second Quarter of 2026, Raises Outlook for the Year

Waiver: Rejection by ACRA for Extension of Time for FYE 31 March 2026; and Update on Indicative Timeline

Response to SGX Queries:

Allot Q2 2026 Financial Results

Natera - Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers

Tower Semiconductor to Participate in August and September Investor Conferences

Gen Z Spending is Expected to Reach $12 Trillion by 2030. Here's Why That Doesn't Matter as Much as Brands Think